{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema.iclusig:0 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema.iclusig%3A0",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.00392,
    "timestamp_received": "2026-04-23T21:25:00.407865+00:00Z",
    "timestamp_returned": "2026-04-23T21:25:00.411785+00:00Z",
    "trace_id": "39d07771-db13-427e-b579-f9dbe1e676d9"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:ema.iclusig:0",
      "indication": "Iclusig is indicated in adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.",
      "initial_approval_date": "2013-07-11",
      "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/iclusig-epar-public-assessment-report_en.pdf",
      "description": "The European Medicines Agency (EMA) has authorized ponatinib for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the p.T315I variant.",
      "raw_biomarkers": null,
      "raw_cancer_type": "Chronic Myeloid Leukemia",
      "raw_therapeutics": "Iclusig (ponatinib)",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:ema.iclusig",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Iclusig (ponatinib) [product information]. EMA.",
        "title": null,
        "aliases": [],
        "description": "Incyte Biosciences Distribution B.V. Iclusig (ponatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf. Revised October 2022. Accessed March 7, 2024.",
        "urls": [
          "https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig",
          "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "ema",
              "type": "Agent",
              "agentType": "organization",
              "name": "European Medicines Agency",
              "description": "Regulatory agency that approves medicines for use in the European Union.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.ema.europa.eu/en/medicines",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "Incyte Biosciences Distribution B.V.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Iclusig",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "ponatinib",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2013-07-11",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2022-10-21",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}